Survival analysis demonstrated that AML patients with a high level of expression of GLI1, PIK3R1, and AKT3 had shorter overall survival (Kaplan–Meier survival analysis) (Figs. 1D and S1B). This evidence concerns the gene GLI1 and acute myeloid leukemia.